FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.
What happened
FDA reviewed import records showing multiple shipments of OTC drug products into the United States that declared WIPRO Consumer Care Vietnam Company, Limited as the drug manufacturer. FDA sent records requests under section 704(a)(4) on June 16 and July 7, 2022, and a follow-up on October 7, 2022, but the firm did not respond. After conflicting statements about US distribution, FDA publicly notified the firm on July 5, 2023, and placed all its drugs on Import Alert 66-79 on August 11, 2023.
What FDA found
The firm refused to permit FDA access to or copying of records that FDA requested under section 704(a).
section 301(e) of the FD&C Act (21 U.S.C. 331(e)); section 704(a) (21 U.S.C. 374(a))The firm did not answer FDA's section 704(a)(4) records requests sent on June 16, July 7, and October 7, 2022, or related communication attempts.
section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
What FDA wants
Respond in writing within 15 working days to CDER-OC-OMQ-Communications@fda.hhs.gov, identifying the response with FEI 3015596082 and ATTN: Yasamin Ameri. The firm may provide information for FDA’s consideration or request an FDA inspection.
Who should pay attention
- US distributors and retailers of Aiken Hand Sanitizer
- companies listing Wipro Unza or WIPRO Consumer Care Vietnam as manufacturer
- quality teams handling FDA section 704(a)(4) records requests
This is a summary. Read the original letter on fda.gov.